Drug intelligence / Profile preview

EPT-101

Development stage: Preclinical
Lead developer: eptivA Therapeutics

Overview

EPT-101 is an investigational analgesic candidate being developed by eptivA Therapeutics for the treatment of chronic pain. Currently in the IND-enabling stage, the drug is part of a pipeline focused on 'Personalized Analgesics.' The development of EPT-101 leverages eptivA's proprietary Pain Cloud® platform, a SaaS-based R&D tool intended to optimize analgesic discovery and precision medicine in pain management. As of early 2026, the company has not publicly disclosed the drug's molecular target, modality (such as small molecule or biologic), or specific mechanism of action, maintaining these technical details as proprietary.

Beyond the preview

Go deeper on EPT-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EPT-101.

Explore the full profile